\
&
Contact us
\
&
Contact us
Published on | 3 years ago
Programmes HorizonEU L+FThe Commission has updated on 30 November 2021 the pre-draft of the Annotated Model Grant Agreement (of all programmes, not only Horizon Europe).
This version has been updated with corporate annotations of Articles 1-6 (i.e. annotations for all programmes). These annotations explain notably personnel costs daily rate calculation with single calculation over the reporting period.
The annotations to the other articles remain those of the pre-draft AGA for HE as previously published on 23 July 2021. These will be updated later on by further batch(es) of corporate annotations for all programmes. We will keep you informed about this process.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
Digital, Industry & Space Horizon Europe Digital Europe AI Continent
The Commission unveiled new features for artificial intelligence (AI) researchers and industry on itsAI-on-Demand platform, including an AI marketplace, an AI development tool that requires minimal coding, as well as secure solutions for generative AI and large language models. The platform, developed jointly by the EU-funded projects AI... read more
Health Digital, Industry & Space AI Continent Deployment: Best use of technologies
The European Commission has launched a procurement procedure for a Virtual Human Twins (VHT) Platform Project Support Office.The main goal of the Project Support Office (PSO) will be to provide support and advice to the Contracting Authority in managing the VHT Platform framework contract and specific contracts. The PSO will ensure h... read more
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
